{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-24-004310","form_type":"8-K","ticker":"NXL","cik":"0001527352","company_name":"Nexalin Technology, Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.835311+00:00","generated_at":"2026-06-01T03:53:08.147808+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa","bullets":["Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.","This is Nexalin's second regulatory approval outside China in 2024.","Brazil has >215M population, >35M with mental health disorders; 9th largest economy.","CEO says approval is springboard into other South American markets; distributor talks underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-24-004310","json":"https://secwatch.observer/filing/0001829126-24-004310.json","markdown":"https://secwatch.observer/filing/0001829126-24-004310.md","text":"https://secwatch.observer/filing/0001829126-24-004310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/0001829126-24-004310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/nexalintech_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:53:08.147808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}